ROCKVILLE, Md., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announces that the Company has entered into a license and distribution agreement with Millennia Holdings, Inc. (“Millennia”) for the Company’s AutoloGel(TM) System in Japan. The AutoloGel(TM) System is the Company’s proprietary, point-of-care device for the production of Platelet Rich Plasma (“PRP”) gel derived from the patient’s own blood and is indicated for use in exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically-debrided wounds. The agreement provides territorial exclusivity for 10 years with the option to extend terms upon agreement by both parties.
